This is not the most recent version of this material.
For an updated version, please see the relevant topic page.
Asthma: Draft Scoping Document
ICER’s initial draft report on interventions for mepolizumab (Nucala, GlaxoSmithKline plc.) for the treatment of severe eosinophilic asthma. This report was open to a public comment period and updated based on comments received.View All Materials on this Topic or Go Back to View More Materials